Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Nanomix Corp NNMX

Healthcare Medical Devices

Nanomix Corporation is engaged in development of mobile point-of-care diagnostics. The Company operates through its Nanomix eLab System platform and assays that provide quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The platform is designed to provide rapid test results in a handheld device at the first point of patient... see more

Add To Watchlist

Recent & Breaking News (OTCPK:NNMX)

Boston Therapeutics Presents Findings of BTI-320, a Novel, Non-Systemic, Non-Hypoglycemic Drug Candidate as Therapy to Manage Blood Glucose at 75th Annual Meeting of the American Diabetes Association

Marketwired June 8, 2015

Boston Therapeutics & University at Buffalo's Translational Pharmacology Research Core Initiates BTI-320 Clinical Trials Alliance in Buffalo, NY and NYC's Chinatown

Marketwired May 28, 2015

Boston Therapeutics, Inc. Reports First Quarter Results and Provides Corporate Update

Marketwired May 20, 2015

Boston Therapeutics Announces Fourth Quarter and Fiscal Year 2014 Financial Results and Provides Corporate Update

Marketwired March 27, 2015

Boston Therapeutics' Affiliate Advanced Pharmaceutical Initiates SUGARDOWN(R) Clinical Trial in Hong Kong

Marketwired March 25, 2015

Boston Therapeutics and Advance Pharmaceutical Expand sugardown(R) Licensing Agreement to Japan; Increases Number of Asian Countries to 16

Marketwired March 17, 2015

WSA Medical Spotlight

Marketwired February 17, 2015

Boston Therapeutics' Hong Kong Affiliate Receives Department of Health Certificate to Initiate SUGARDOWN(R) Clinical Trial

Marketwired January 27, 2015

Boston Therapeutics' sugardown(R) Significantly Reduces Glucose, Fructose and Insulin Levels in Sugary Soft Drinks

Marketwired January 20, 2015

Boston Therapeutics to Present at 8th Annual OneMedForum Conference in San Francisco

Marketwired January 7, 2015

Boston Therapeutics' sugardown(R) Shown to Reduce Glucose Levels Following Consumption of Sugary Beverages

Marketwired January 6, 2015

Boston Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of BTI-320 to Treat Type ll Diabetes and Weight Loss

Marketwired December 10, 2014

Boston Therapeutics and Advance Pharmaceutical Expand Agreement to Market sugardown(R) in 12 Additional Countries in Asia

Marketwired November 21, 2014

Boston Therapeutics Initiates Clinical Study at Sydney University to Evaluate sugardown(R) With Sugary Beverage Consumption

Marketwired November 17, 2014

Boston Therapeutics Reports Third Quarter Results and Provides Corporate Update

Marketwired November 7, 2014

Boston Therapeutics Announces the North America Branding of sugardown(R): A New Natural Product That Helps Maintain Healthy Blood Sugar Levels

Marketwired November 3, 2014

Boston Therapeutics Reports Topline U.S.-Based Phase IIb Study Results of BTI-320 in Patients With Type 2 Diabetes

Marketwired October 9, 2014

Boston Therapeutics Appoints David S.H. Bell, MB, FACP, FACE to Its Medical Advisory Board

Marketwired October 8, 2014

Boston Therapeutics Files Patent Application for Novel Therapeutic Uses of BTI-320

Marketwired October 7, 2014

Boston Therapeutics Appoints Jan Brinkman, M.D., Ph.D. and Alan M. Hoberman, Ph.D. to Board of Directors

Marketwired October 1, 2014